Home News

The use of Replicine™ Functional Keratin® to advance wound care in conditions ranging from Epidermolysis Bullosa to chronic wound care and acceleration of healing of complex wounds will be presented by clinicians at SAWC 2015, San Antonio, TX, USA, April 29-May 3.

Keraplast Technologies will be available for further discussion on the Replicine™ Functional Keratin®, the new paradigm in wound healing, at booth 252. Please join us at the forefront of wound care.

Poster Presentations:

An evaluation of a keratin gel to accelerate healing and improve care for dystrophic epidermolysis bullosa patients, G Tadini, MD, U.O.S. Dermatologia Pediatrica – Dipartimento di Medicina Interna e Specializzazioni Mediche, IRCCS Ospedale Maggiore, Milano, Italy.

A clinical trial of a keratin gel to accelerate healing and improve comfort post haemorrhoidectomy, I Kolossa, MD, EBSQ, Intus Digestive and Colorectal Care, Christchurch, New Zealand.

Keratin dressings in the management of epidermolysis bullosa, J Denyer, Great Ormond Street Hospital, London, United Kingdom.

Effectiveness of topical therapies based on keratin for pressure sore in spinal cord injury, M Belci, MD, T Simone, MD, PRM, R Singhal, MD, L Stephen, RN, National Spinal Injury Centre, Stoke Mandeville, United Kingdom, University of Roma Tor Vergata, Italy and Burwood Hospital Spinal Unit, Christchurch, New Zealand.

Novel use of a keratin gel to epithelise areas with delayed healing as part of a procedure for giant nevus. J Jutkiewicz-Sypniewska, MD, M Plewko, MD, Department of Paediatric Surgery, Children’s Hospital of Professor J. Bogdanowicz, Warsaw, Poland

Posted in Company News |

Keraplast Technologies announced today the appointment of SpringMedical of the Netherlands as its exclusive distribution partner for keragelT® for management of epidermolysis bullosa in the Netherlands, Belgium and Luxembourg. Dr Clive Marsh, Wound Care Development Manager for Keraplast, said “keragelT® is being increasingly used as the product of choice by clinicians and experts in management of epidermolysis bullosa all over the world, but in particular in the EU. To extend that availability to the Netherlands, Belgium and Luxembourg is a significant addition and we believe will be welcomed by families living with EB in this region.” Dr Rob Kelly, Interim Chief Executive of Keraplast added “increasing distribution for our Replicine™ Functional Keratin® wound care technology in the EU is a strategic goal for us, and our actions over the last 12 months have created a strong and stable foundation for future business growth with the majority of the EU now covered. We are proud to partner with SpringMedical as we believe they share our philosophy of delivering the best care available to meet this unmet clinical need and represent the best way to get keragelT® to families living with EB in the region” Harry Wierbos, Chief Executive of SpringMedical said “Families in the Netherlands, Belgium and Luxembourg expect the highest standard of care to be available to them. SpringMedical consistently provides products backed by strong clinical evidence to deliver that care and welcomes the addition of the innovative product keragelT® to its portfolio. The EB community in Benelux can continue to expect the latest wound care innovations to be available from SpringMedical.”

For enquiries from Netherlands, Belgium or Luxembourg please contact SpringMedical +31 55 3560544, http://www.springmedical.nl, This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Posted in Company News |

German medical distribution company Memax has been appointed as distributor for keragelT®, the advanced wound care product developed by Keraplast using its proprietary Replicine™ Functional Keratin® technology. Dr Clive Marsh, Wound Care Development Manager for Keraplast, said “We have been working for several years with specialist clinical groups and the international DEBRA organization to establish keragelT® as the best wound management option for patients living with epidermolysis bullosa. This includes groups in Germany and Austria as well as the UK and many Scandinavian countries. As more expert groups take on keragelT® as an important wound management tool, it is essential to be able to get keragelT® to patients in a practical and efficient way. We are very excited about joining with Memax to help this happen for the families in Germany and Austria.” Dr Rob Kelly, Interim Chief Executive of Keraplast added “To make a difference in the management of EB our ground breaking keragelT® product has to be proven as effective in the hands Doctors, Nurses and the families dealing with wound care every day. In addition it has to be easily accessible and where possible covered by national reimbursement or insurance programmes. All these factors have come together in the US, UK, Australasia and several other countries. With partnership with Memax we are confident the factors will align quickly for Germany also.”

Joachim Brinkmeir, CEO of Memax said “keragelT® is a highly innovative approach to epidermolysis bullosa wound management and is backed by a high standard of peer review data. This is very consistent with the high performance products that Memax has built a strong reputation on and we are excited to now be offering this to the clinical community in Germany.

For enquiries from Germany or Austria please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it or visit http://www.memax.info/. From Germany phone 0761/1514668-0. From Austria or international phone 0049761/1514668-0.

Posted in Company News |

Keraplast and our distribution partners for keragelT® around the world would like to say thank you to the clinicians, nurses and families living with EB that have come to meet us over recent months. We have made many new friends and contacts, in the US at the DEBRA Patient Care Conference, in France at the DEBRA International Congress, in South Africa at the Dermatology Society of SA Annual Congress and in Norway at the Norwegian DEBRA national meeting.

As a result of feedback from people using keragelT® we have created this page of tips and tricks on how best to use keragelT® to manage EB wounds.


We look forward to working more with DEBRA and the EB community in all of these regions. Latest information on keragelT® can always be found on our website here


And by contacting us here


Posted in Company News |

San Antonio, USA, September 15th 2014. Keraplast announced today that a $1.6M grant had been awarded to the research institute AgResearch for a programme of research focused on keratin based wound care. The four year programme, led by senior scientist Dr Stefan Clerens from the Proteins and Biomaterials Team will extend knowledge of the bioactive performance of keratin proteins in a wound healing environment leading to the development of more advanced and higher performance keratin wound care devices to better address unmet clinical needs in wound care.

Keraplast Technologies is the commercial partner in the programme and collaborators include scientists from the University of Miami Miller School of Medicine.

Dr Rob Kelly, Keraplast Technologies Chief Scientific Officer and Interim Chief Executive Officer said “As the only company with keratin based wound care products in the market and in use in clinics around the world we are excited to be partnering with AgResearch in this scientific programme. We have consistently been at the forefront of keratin science and have a demonstrated track record of transforming that science into clinical benefits to make a difference to the lives of patients with unmet needs in wound care. This groundbreaking research from a world class team will ensure we maintain our position at the leading edge of applying keratin science in medicine.”

Dr Sonya Scott, key senior scientist in the programme, said “This is extremely exciting research, as it is a combinations of insight in biological modes of action and direct commercial application with real health outcomes. A core strength of AgResearch is the translation of excellent science into commercial outcomes, and working with the Keraplast team, and our collaborators at the University of Miami, will ensure that continues.”

Dr Stefan Clerens, Science Team Leader in the Proteins and Biomaterials Team added “The Protein and Biomaterials Team is world class in the field of keratin science and proteomics. Gaining the support from the government recognizes that expertise and gives us the foundation to further elucidate the biological mechanisms and performance of keratin proteins and peptides.”

The grant has been awarded under the High-Value Manufacturing and Services Research Fund as part of the Ministry of Business, Innovation & Employment and is for research commencing in October 2014.

For more information contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it or This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Posted in Company News |

San Antonio, USA, July 10th 2014. Keraplast Technologies announced today that following evaluation at the specialist epidermolysis bullosa clinic at Great Ormond Street Hospital in London under the supervision of leading DEBRA Nurse Jackie Denyer, the keratin wound care gel keragelT® has been placed on the UK drug tariff list. This means clinicians and carers in the UK can now choose keragelT®, the latest tool for EB wound management, and have confidence that the care will be funded by the NHS.

In addition, H&R Healthcare has been appointed as UK distributor for the Keraplast wound care product range, including the keratin based products keragelT®, keragel®, keramatrix® and kerasorb®. This means that the only keratin based wound care products on the market are now available through the leading supplier of specialist wound care innovations in the UK.

Dr Rob Kelly, Interim Chief Executive Officers of Keraplast Technologies said “The unique approach to wound care that Replicine Functional Keratin provides is clearly solving unmet clinical needs in several disciplines, leading to growing interest in Europe. We are very pleased to be able to make a difference in the management epidermolysis bullosa and work closely with specialist clinics such as Great Ormond Street Hospital in London and EB Haus in Austria. Having keragelT® funded on the UK Drug Tariff will make a significant difference to families in the UK living with EB as they now have the latest advancement available to them. We are also seeing strong interest from groups working at the forefront of chronic wound care, such as the pressure ulcer group at Stoke Mandeville hospital who recently presented work on keragel® and keramatrix® at the 16th National Congress on Paraplegic Medicine in Italy.” He added “partnering with H&R Healthcare is perfect for us as they are clearly well recognised as being specialists at bringing wound care innovations into the UK healthcare system and we share the common goal of using innovation to improving patient outcomes.”

Mike Hoskins, Chief Executive Officer of H&R Healthcare said “our philosophy is

to offer innovative products that give the best overall value to the NHS, measured by patient outcomes and overall cost effectiveness. The Keraplast product range clearly provides this and we are excited about introducing this innovation to the UK.”

For product enquires from the UK please contact H&R Healthcare Ltd, Tel: +44 (0)1482 631606, Email:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it , web http://www.hrhealthcare.co.uk/index.html

Posted in Company News |

Replicine™ Functional Keratin® advanced wound care technology is now available in Denmark, Norway and Sweden following appointment of Med-Vice (Denmark and Norway) and MedPre AB (Sweden) as distributors of Keraplast wound care products.

Dr Rob Kelly, Interim Chief Executive of Keraplast said “health care in Scandinavia is well recognized as among the best in the world. The improved clinical outcomes available using Replicine Functional Keratin wound care products, in particular in management of epidermolysis bullosa, but also in care for chronic wounds and burns, is creating demand from clinicians in these regions that are used to providing their patients the best care available. We are pleased to have found local partners that are respected by the health care community and understand well how to get the best care to patients as easily as possible.”

Marie Louise Little, CEO of Med-Vice said “Interest in keragelT from the epidermolysis bullosa community is very high in many parts of Europe, including Denmark and Norway. Local clinicians always want to offer the best care, in particular to those in most need such as families living with EB and we are excited to now have that option available”

Magnus Precht, CEO of MedPre said “Replicine Functional Keratin is truly innovative and is well supported with published clinical data. It complements well the other advanced innovation that Med Pre offers to the wound care community and we are already seeing strong interest from the clinical community”

For enquires from Denmark or Norway contact Med-Vice on +45 4576 7626, www.med-vice.com or This e-mail address is being protected from spambots. You need JavaScript enabled to view it

For enquiries from Sweden contact MedPre AB on +46-708-205041 or at www.medpre.se.

Posted in Company News |

Over the last 12 months 5 new peer review papers were published on clinical outcomes of Replicine Functional Keratin wound care products. These included randomized controlled studies of scar healing and donor site healing, as well as a case series study of chronic wounds. These peer review publications are in addition to 9 conference presentations in the same period and consolidate the substantial evidence base supporting clinical use of Replicine Functional Keratin wound care products to manage a wide range of wound types.

Dr Robert Allen Smith, Medical Director of Keraplast Technologies said “Evidence based practice underpins the clinical choices made in wound care. Peer review science is the gold standard for establishing the required evidence base, and as a result of the increasing evidence base for Replicine Functional Keratin, clinicians around the world are embracing keratin as the treatment method of choice.”

Dr Rob Kelly, Chief Scientific Officer of Keraplast Technologies added “The fact that Replicine Functional Keratin wound care products are established in markets around the world with the necessary regulatory approvals and a growing distribution network means that making a good, evidence based decision to manage wounds using keragel, keramatrix or kerasorb, is getting easier and easier. From managing the severe skin disorder epidermolysis bullosa to improving outcomes for chronic wounds, burns, or reducing scars, the clinical decisions being made to use Replicine Functional Keratin are backed by published data.”

The latest publications on Replicine Functional Keratin wound care are listed here: http://www.keraplast.com/evidence-based-wound-care

Keraplast Technologies will be discussing the latest clinical findings on keratin wound care with forward thinking clinicians at the SAWC convention in Orlando, Florida, April 24-26 2014 and the European Wound Management Association (EWMA) conference in Madrid May 14-16 2014

Posted in Company News |

The latest clinical research in the treatment of burns, diabetic foot ulcers, chronic venous ulcers and surgical wounds using keratin protein technology will all be showcased at spring SAWC, Denver May 1-5 2013.

Replicine™ Functional Keratin® wound care is rapidly becoming established as the treatment of choice at forward thinking hospitals and wound centers across the US. Thought leading physicians from several US facilities will present their latest findings on keratin wound care in a series of poster presentations. Further details on keratin wound care developments and how Replicine™ Functional Keratin® can improve your patient outcomes and reduce cost of care can be found by visiting Keraplast Technologies at booth 546, or by viewing the following posters at the conference.

Use of keratin gel technology to speed healing of hard to heal wounds.K. Nicki Blasiole MSN, RN, CWOCN, Elliot Mostow MD, MPH
Akron General Medical Center, Wound Healing and Limb Preservation Center

The Use of Keratin Dressings in the Treatment of Venous Ulcers
Terry Treadwell, MD, FACS, Donna Walker, LPN, Betty Jean Nicholson, CNA, Maggie Taylor, NA
Institute for Advanced Wound Care, Montgomery, Alabama

Keratin dressings for effective wound care management in acute superficial and partial thickness burn injuries
Dr Fiona Loan, Dr Clive Marsh, Mrs Sharon Cassidy, Mr Jeremy Simcock
Department of Plastic and Reconstructive Surgery, Christchurch Hospital, New Zealand

Keratin Products in the Treatment of an Unusual Acute Surgical Wound with Tendon Exposure
Virginia Capasso, PhD, ANP-BC, CWS, Massachusetts General Hospital.

A new approach to diabetic foot ulcers using keratin gel technology
Farheen Wahid, BA, Shrunjay R. Patel, BSc, Stephanie Wu, MD. Dr. William M. Scholl College of Podiatric Medicine
Rosalind Franklin University

A Randomised Controlled Trial of Functional Keratin Dressings for Treatment of Chronic Venous Leg Ulcers
Wen Qing Fu et al.The Medical Academy of Soochow University; Suzhou Jiangsu 215123, China.

Posted in Company News |

SAN Antonio, USA, February 5, 2013. Keraplast technologies announced today the listing of Replicine™ Functional Keratin® wound care products on the Federal Supply Schedule (FSS). VA health care facilities and active military organizations, such as the Department of Defense, are now able to access Replicine™ Functional Keratin® wound care products through the military supplies distributor Marathon Medical.

Dr Rob Kelly, CEO of Keraplast Technologies, said “Replicine Functional Keratin is a new paradigm in wound healing, providing a significant advancement in the care chronic wounds, such as venous leg ulcers and diabetic foot ulcers, as well as acute wounds such as burns and trauma injuries. Keraplast is proud to be able to offer this advancement for the care of veterans and active military personnel.”

The products keragel™, keramatrix® and kerasorb® are available on the FSS through established supplier Marathon Medical. John St Leger, CEO of Marathon Medical said “Marathon has been serving the needs of our soldiers and veterans for 11 yrs. We strive of offer the most advanced and effective healthcare products available and the Replicine Functional Keratin advanced wound care range ensure we continue to provide the best care possible.”

For more information on accessing the products from Marathon Medical visit http://www.marathonmed.com/index.html or call 877.431.4753.

To learn more about Replicine Functional Keration wound care products visit http://www.keraplast.com/wound-care   or call 210 494 5596.

About Keraplast

Keraplast Technologies LLC, a privately held company founded in 1996, is the world’s leading developer and manufacturer of keratin products. Headquartered in San Antonio, Texas, Keraplast manufactures Replicine™ Functional Keratin® wound care products with FDA and CE mark clearance for sale around the world, as well as a wide range of skin care, hair care and nutritional solutions using proprietary keratin technology.

About Marathon Medical

Marathon Medical’s management has been in the medical supply business for over 80 years and our company has been in existence for over 11 years.  We distribute nationally with LTL and package contracts with many of the major carriers.  Please take a few minutes to visit our website, www.marathonmed.com and you will see that we are committed to the military member, the veteran and the service disabled veteran.  Since I have and do belong to each of these categories I have a serious devotion and commitment to each.  This is more than just a job to us.  You will note that on the last page of our website that we back up our words with action.  We pledge a percentage of our sales quarterly to two different veteran charities, American Freedom Foundation and the Wounded Warrior Project.

Please note that we are independently verified by The Center For Veterans Enterprise (CVE) that John St. Leger is a SDVOSB and he is 100% owner of Marathon Medical.

Posted in Company News |